Skip to content
request access

the Circle. · CGTI 2027 · Berlin

For the patientwho cannot wait.

Uwe Gottschalk  ·  Conference Chair  ·  Operating Partner, Keensight Capital

What delivers.

What sustains.

Who reaches the patient.

10–11 February 2027 · Hotel Palace Berlin · Invited Audience
the Why

The pathway that holds. The infrastructure between vector and patient is being built.

What delivers.  ·  What sustains.  ·  Who reaches the patient.

Why.

Less noise. More signal.

01

Every cell and gene therapy leader carries the same weight. How does clinical proof become patient access at scale. The pathway that holds. The infrastructure between vector and patient is still being built.

02

The white space is the room that holds the conversation differently. Closed-door. By invitation. End-user led. No expo hall. No vendor pitch. A circle for the leaders closing the gap between science and the patient who cannot wait.

03

the Conversation. CGTI is that room. Senior cell and gene therapy leadership convened around the work that compounds. Vector manufacturing. Process intensification. CDMO strategy. Regulatory submission. Less noise. More signal.

04

Who attends. Senior faculty drawn from the leaders who own the programme, sign the batch record and carry the accountability. Announced in cadence with the programme.

Thesis · The Room

Who reaches
the patient.

Cell & Gene Therapy Innovation 2027

10–11 February 2027 Hotel Palace Berlin Invited Audience Only

For decision makers from small biotech to global pharma. For the patients. We must do better. We must do better.

The gap.

Cell and gene therapy moves faster than the infrastructure designed to deliver it. Vector manufacturing capacity is still the bottleneck. The compliance gap between model output and patient accountability has never been formally closed. The leaders who carry that accountability have not had the room they need.

The Conversation.

CGTI convenes the leaders building the infrastructure that closes that gap · across viral vector manufacturing · cell therapy process development · CDMO strategy · regulatory strategy and patient access. The corridor where CGT ambition becomes clinical supply · or breaks. The Conversation is where the leaders who carry the accountability meet before the patient does.

The decision.

What delivers. What sustains. Who reaches the patient. Three questions the room must hold before the process locks. For the leaders who own the programme, sign the batch record and are accountable for the gap no one has formally closed.

Uwe Gottschalk

Conference Chair · Operating Partner, Keensight Capital

In the Conversation

The leaders.

Faculty announced in cadence with the programme.

photo from the Circle forum, Cell and Gene Therapy Innovation, Hotel Palace Berlin

The room.

Cell & Gene Therapy Innovation · Berlin · 2027

"

Not a conference. A room where the work compounds.

Uwe Gottschalk · Conference Chair · CGTI 2027

the circle. forum · in the room

Where it convenes.

cgti.ai · the years before · by GBX Circle

photo from the Circle forum, Cell and Gene Therapy Innovation, Hotel Palace Berlinin the room · CGTI
photo from the Circle forum, Cell and Gene Therapy Innovation, delegates in conversationthe room · GBX Circle
photo from the Circle forum, Cell and Gene Therapy Innovation, plenary sessionthe conversation · CGTI
photo from the Circle forum, Cell and Gene Therapy Innovation, networkingin the room · CGTI
photo from the Circle forum, Cell and Gene Therapy Innovation, the room assembledthe room assembled · CGTI
the circle. forum · Invited to the Room

The room.

By invitation. By relevance. By room.

Up to

150

senior leaders

Ratio

80/20

end-user · partner

Format

Two
days

closed-door

By invitation. By relevance. By room.

The principals · By organisation

The principals.

The leaders who own the programme, sign the batch record and carry the accountability for what reaches the patient.

Pharma · Biotech · CDMO · Academic Medical

Novartis Gene Therapies Bristol Myers Squibb Roche Boehringer Ingelheim WuXi Advanced Therapies Bayer AG AstraZeneca Sanofi UCB BioNTech Moderna Takeda Vertex Pharmaceuticals Catalent Gene Therapy Rentschler Biopharma Cytiva Asahi Kasei Bioprocess SGS Novo Nordisk Keensight Capital
Partners · In the room.

The organisations.

CGTI 2027 · Berlin.
Who attends.

Key partners · confirmed

Asahi Kasei Bayer BioNTech Boehringer Ingelheim Bristol Myers Squibb Cytiva

the circle. forum · Partner Positions

By request.
By invitation.

Partner packages and investment are shared directly.
Enter your access code to continue.

No access code? Request the prospectus →

Relationship · The Year

The year.

Not the forum. The relationship.

Q 1

The briefing.

Pre-forum strategic briefing. The room. The roster. The reason.

Q 2

The forum.

CGTI held inside each forum of the Conversation. Two days. Closed-door. End-user led.

Q 3

The follow.

Named delegate follow-through. Curated meeting introductions.

Q 4

The intelligence.

Quarterly intelligence briefing from the Conversation Team.

A position. Not a placement.

the circle. · access

CGTI 2027 · Request Access

The room
is taking
shape.

The prospectus is not public. Shared directly with the organisations that belong. Who attends.

"Not a conference. A room where the work compounds."

Uwe Gottschalk · Conference Chair · CGTI 2027

Contact · For the Conversation

The conversation.

The room. The conversations. The decisions.

Manager · Life Sciences

Herbert Ryan

Life Sciences · CGTI

Co-Producer & Operations

Sheryll Lusk

Operations · the circle.